Defence Therapeutics Inc. DTCFF
Set alert
0.26 USD 0.00 -0.42%
At close · Oct 30
0.26 Day range 0.26
0.2418 52-week range 0.7787
- YTD
- -53.37%
- 1 year
- -55.58%
- Open
- 0.26
- Prev close
- 0.2611
- Mkt cap
- 19.70M
- Vol
- 9.96K
- Avg vol
- 10.15K
- EPS
- -0.08
- P/E
- 0.00
More statistics
- Low
- 0.26
- High
- 0.26
3M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
News
- Defence Therapeutics Announces Convertible Debenture Interest Payment
- Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
- Defence Therapeutics Inc. (OTCMKTS:DTCFF) Stock Short Interest Report for September
- Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
- Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
- Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities
- Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
- Defence Therapeutics Provides Updates on Sharing Agreement
- Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
- Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Your note
Sign in to keep a note on DTCFF — it syncs with the Stock Master app.